Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

May 01, 2011 (Vol. 31, No. 9)

Biopharma R&D Spending for 2012 Under Seige

Restructuring and Budgetary Cuts Threaten to Lower Industry Expenditures

  • On March 16, Novartis said that it will decrease R&D in the U.K. with reports putting the number of jobs to be cut between 400 and 550. This places the pharma giant in the company of GlaxoSmithKline, Merck & Co., Pfizer, and Roche. Over the past two years all ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.